Key result
Transcatheter aortic valve implantation significantly reduced mitral regurgitation severity, with effective regurgitant orifice area decreasing from 24.4 to 11.2 mm2 (P<0.001).
Why the study?
Does TAVI improve mitral regurgitation severity in patients with baseline MR ≥ 2+?
Population
35 patients with mitral regurgitation graded ≥ 2+ undergoing transcatheter aortic valve implantation
Design
Cohort
Follow-up
3 months
Authors
Loading...
TAVI was associated with reduced MR severity; leaves open outcome impact and valve-type effects in this cohort.
Cohort (n=35)
Does TAVI improve mitral regurgitation severity in patients with baseline MR ≥ 2+?
Absolute Event Rate: 11.2% vs 24.4%
p-value: p=<0.001
TAVI significantly improves mitral regurgitation severity in patients with baseline MR ≥ 2+, with subgroup analysis suggesting this may be related to the type of valve implanted.
Giordana et al. (2012) conducted a cohort in Mitral Regurgitation (n=35). Transcatheter aortic valve implantation (TAVI) vs. Baseline (pre-TAVI) was evaluated on Effective regurgitant orifice area (EROA) in mm2 (p=<0.001). Transcatheter aortic valve implantation significantly reduced mitral regurgitation severity, with effective regurgitant orifice area decreasing from 24.4 to 11.2 mm2 (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: